Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Record breaking Pharma M&A for 2022?

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Nov 24, 2021 12:28pm

174 Views

Post# 34161945

RE:RE:Record breaking Pharma M&A for 2022?

Hey Canadafan, serious question for you as you seem to have an ear closer than most. Do you think it would be prudent for AN to use the bio-markers in their upcoming phase 3 trial considering all of the work and time that has gone into the aware1 trial to obtain a biomarker as requested by the fda.
It would make sense and supposedly increase the chance of success and would be in both companies best interest. I have asked this of onc but with no response.

<< Previous

Bullboard Posts

Next >>

Nintendo stock jumps despite Q2 financials, new console news